

**BIOLIDICS LIMITED**  
(Company Number: 200913076M)  
(Incorporated in the Republic of Singapore)

**RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 28 APRIL 2022**

The board of directors (“**Board**” or “**Directors**”) of Biolidics Limited (the “**Company**”) wishes to announce that pursuant to Rule 704(15) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) (“**Catalist Rules**”), the proposed resolutions relating to the matters as set out in the notice of Annual General Meeting (“**AGM**”) dated 13 April 2022, were duly passed by shareholders of the Company (“**Shareholders**”) by way of poll at the AGM held by way of electronic means on 28 April 2022.

**Poll results**

Resolution number and details		Total no. of shares represented by votes for and against the relevant resolution	For		Against	
			No. of shares	As a percentage of total no. of votes for and against the resolution	No. of shares	As a percentage of total no. of votes for and against the resolution
Ordinary Business						
1.	Adoption of the audited financial statements of the Company for the financial year ended 31 December 2021, the directors’ statement and the auditors’ report thereon	68,840,000	68,825,800	99.98%	14,200	0.02%
2.	Approval of the payment of directors’ fees of S\$235,000 for the financial year ending 31 December 2022, payable quarterly in arrears	68,064,200	68,050,000	99.98%	14,200	0.02%
3.	Re-election of Mr Chen Johnson as a director of the Company (“ <b>Director</b> ”)	68,840,000	68,825,800	99.98%	14,200	0.02%
4.	Re-election of Mr Gavin Mark McIntyre as a Director	68,840,000	68,825,800	99.98%	14,200	0.02%
5.	Re-election of Mr Song Tang Yih as a Director	68,064,200	68,050,000	99.98%	14,200	0.02%
6.	Re-election of Mr Ian David Brown as a Director	68,840,000	68,825,800	99.98%	14,200	0.02%
7.	Re-appointment of Messrs Ernst & Young LLP as the Company’s auditors	68,840,000	68,825,800	99.98%	14,200	0.02%
Special Business						
8.	Authority to allot and issue shares in the capital of the Company (“ <b>Shares</b> ”)	68,840,000	68,825,800	99.98%	14,200	0.02%
9.	Authority to grant awards and to allot and issue Shares pursuant to the Biolidics Performance	68,064,200	68,050,000	99.98%	14,200	0.02%

Resolution number and details	Total no. of shares represented by votes for and against the relevant resolution	For		Against	
		No. of shares	As a percentage of total no. of votes for and against the resolution	No. of shares	As a percentage of total no. of votes for and against the resolution
	Share Plan ("PSP")				
10.	Renewal of the Interested Person Transactions Mandate	8,704,600	8,690,400 99.84%	14,200	0.16%

### **Re-election of Directors**

Mr Chen Johnson, having been re-elected as a Director, remains as a Non-Executive Non-Independent Director and Founder, and a member of the Nominating Committee.

Mr Gavin Mark McIntyre, having been re-elected as a Director, remains as the Non-Executive Independent Chairman and the Chairman of the Audit Committee. He is considered to be independent for the purpose of Rule 704(7) of the Catalist Rules.

Mr Song Tang Yih, having been re-elected as a Director, remains as an Executive Director and the Chief Executive Officer.

Mr Ian David Brown, having been re-elected as a Director, remains as an Independent Director and a member of the Audit Committee, Nominating Committee and Remuneration Committee. He is considered to be independent for the purpose of Rule 704(7) of the Catalist Rules.

### **Abstention from Voting**

Details of parties who are required to abstain from voting on any resolution(s):

Resolution no.	Name	No. of Shares
Resolution 2	Chen Johnson and Song Tang Yih	3,524,100
Resolution 9	Shareholders who are eligible to participate in the PSP	4,511,500
Resolution 10	Chen Johnson and Clearbridge BSA Pte. Ltd.	62,883,700

### **Appointment of Scrutineer**

DrewCorp Services Pte Ltd was appointed as the scrutineer for the polling process at the AGM.

### **By Order of the Board**

Gavin Mark McIntyre  
Non-Executive Independent Chairman  
28 April 2022

---

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Catalist Rules.*

*This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr. Lim Hoon Khiat, Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*